Combined splenectomy does not improve survival in radical total gastrectomy for advanced gastric cardia cancer

Wen Liang Fang, Kuo Hung Huang, Chew Wun Wu, Jen Hao Chen, Su Shun Lo, Mao Chih Hsieh, King Han Shen, Anna Fen Yau Li

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background/Aims: Splenectomy is the most common combined organ resection in the surgical management for gastric cardia cancer. The role of combined splenectomy is still controversial. Methodology: From January 1998 to December 2006, a total of 174 patients received radical total gastrectomy for advanced adenocarcinoma of cardia. Patients with previous gastric surgery or tumor invasion of pancreas or spleen were excluded. Among them, 115 patients were enrolled in this study. Patients were divided into group 1 (splenectomy, n=47) and group 2 (spleen preservation, n=68). Their clinicopathological characteristics were compared. Results: Multivariate analysis showed that only tumor size and lymphovascular invasion were two independent indicators of survival. The surgically-related morbidity and mortality rates were similar between the two groups. Among the 3 patients with splenic hilar lymph nodes metastasis, all of them had large tumor size (≥4cm), advanced stage (stage III and IV) and tumor center located at the posterior wall of stomach. The 5-year overall survival for advanced cancer was similar (57.1% vs. 60.2%, p=0.681). Conclusions: Splenectomy does not improve overall survival in the management of advanced gastric cardia cancer. Splenectomy has limited clinical benefits except for large advanced tumors located at the posterior wall of stomach.

Original languageEnglish
Pages (from-to)1150-1154
Number of pages5
JournalHepato-Gastroenterology
Volume59
Issue number116
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Cardia
Splenectomy
Gastrectomy
Stomach Neoplasms
Survival
Neoplasms
Stomach
Spleen
Pancreas
Adenocarcinoma
Multivariate Analysis
Lymph Nodes
Neoplasm Metastasis
Morbidity
Mortality

Keywords

  • Spleen preservation
  • Splenectomy
  • Survival

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Combined splenectomy does not improve survival in radical total gastrectomy for advanced gastric cardia cancer. / Fang, Wen Liang; Huang, Kuo Hung; Wu, Chew Wun; Chen, Jen Hao; Lo, Su Shun; Hsieh, Mao Chih; Shen, King Han; Li, Anna Fen Yau.

In: Hepato-Gastroenterology, Vol. 59, No. 116, 06.2012, p. 1150-1154.

Research output: Contribution to journalArticle

Fang, Wen Liang ; Huang, Kuo Hung ; Wu, Chew Wun ; Chen, Jen Hao ; Lo, Su Shun ; Hsieh, Mao Chih ; Shen, King Han ; Li, Anna Fen Yau. / Combined splenectomy does not improve survival in radical total gastrectomy for advanced gastric cardia cancer. In: Hepato-Gastroenterology. 2012 ; Vol. 59, No. 116. pp. 1150-1154.
@article{6a0b30abac114e8bbf487ae5d84b2c27,
title = "Combined splenectomy does not improve survival in radical total gastrectomy for advanced gastric cardia cancer",
abstract = "Background/Aims: Splenectomy is the most common combined organ resection in the surgical management for gastric cardia cancer. The role of combined splenectomy is still controversial. Methodology: From January 1998 to December 2006, a total of 174 patients received radical total gastrectomy for advanced adenocarcinoma of cardia. Patients with previous gastric surgery or tumor invasion of pancreas or spleen were excluded. Among them, 115 patients were enrolled in this study. Patients were divided into group 1 (splenectomy, n=47) and group 2 (spleen preservation, n=68). Their clinicopathological characteristics were compared. Results: Multivariate analysis showed that only tumor size and lymphovascular invasion were two independent indicators of survival. The surgically-related morbidity and mortality rates were similar between the two groups. Among the 3 patients with splenic hilar lymph nodes metastasis, all of them had large tumor size (≥4cm), advanced stage (stage III and IV) and tumor center located at the posterior wall of stomach. The 5-year overall survival for advanced cancer was similar (57.1{\%} vs. 60.2{\%}, p=0.681). Conclusions: Splenectomy does not improve overall survival in the management of advanced gastric cardia cancer. Splenectomy has limited clinical benefits except for large advanced tumors located at the posterior wall of stomach.",
keywords = "Spleen preservation, Splenectomy, Survival",
author = "Fang, {Wen Liang} and Huang, {Kuo Hung} and Wu, {Chew Wun} and Chen, {Jen Hao} and Lo, {Su Shun} and Hsieh, {Mao Chih} and Shen, {King Han} and Li, {Anna Fen Yau}",
year = "2012",
month = "6",
doi = "10.5754/hge10429",
language = "English",
volume = "59",
pages = "1150--1154",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "116",

}

TY - JOUR

T1 - Combined splenectomy does not improve survival in radical total gastrectomy for advanced gastric cardia cancer

AU - Fang, Wen Liang

AU - Huang, Kuo Hung

AU - Wu, Chew Wun

AU - Chen, Jen Hao

AU - Lo, Su Shun

AU - Hsieh, Mao Chih

AU - Shen, King Han

AU - Li, Anna Fen Yau

PY - 2012/6

Y1 - 2012/6

N2 - Background/Aims: Splenectomy is the most common combined organ resection in the surgical management for gastric cardia cancer. The role of combined splenectomy is still controversial. Methodology: From January 1998 to December 2006, a total of 174 patients received radical total gastrectomy for advanced adenocarcinoma of cardia. Patients with previous gastric surgery or tumor invasion of pancreas or spleen were excluded. Among them, 115 patients were enrolled in this study. Patients were divided into group 1 (splenectomy, n=47) and group 2 (spleen preservation, n=68). Their clinicopathological characteristics were compared. Results: Multivariate analysis showed that only tumor size and lymphovascular invasion were two independent indicators of survival. The surgically-related morbidity and mortality rates were similar between the two groups. Among the 3 patients with splenic hilar lymph nodes metastasis, all of them had large tumor size (≥4cm), advanced stage (stage III and IV) and tumor center located at the posterior wall of stomach. The 5-year overall survival for advanced cancer was similar (57.1% vs. 60.2%, p=0.681). Conclusions: Splenectomy does not improve overall survival in the management of advanced gastric cardia cancer. Splenectomy has limited clinical benefits except for large advanced tumors located at the posterior wall of stomach.

AB - Background/Aims: Splenectomy is the most common combined organ resection in the surgical management for gastric cardia cancer. The role of combined splenectomy is still controversial. Methodology: From January 1998 to December 2006, a total of 174 patients received radical total gastrectomy for advanced adenocarcinoma of cardia. Patients with previous gastric surgery or tumor invasion of pancreas or spleen were excluded. Among them, 115 patients were enrolled in this study. Patients were divided into group 1 (splenectomy, n=47) and group 2 (spleen preservation, n=68). Their clinicopathological characteristics were compared. Results: Multivariate analysis showed that only tumor size and lymphovascular invasion were two independent indicators of survival. The surgically-related morbidity and mortality rates were similar between the two groups. Among the 3 patients with splenic hilar lymph nodes metastasis, all of them had large tumor size (≥4cm), advanced stage (stage III and IV) and tumor center located at the posterior wall of stomach. The 5-year overall survival for advanced cancer was similar (57.1% vs. 60.2%, p=0.681). Conclusions: Splenectomy does not improve overall survival in the management of advanced gastric cardia cancer. Splenectomy has limited clinical benefits except for large advanced tumors located at the posterior wall of stomach.

KW - Spleen preservation

KW - Splenectomy

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84861363111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861363111&partnerID=8YFLogxK

U2 - 10.5754/hge10429

DO - 10.5754/hge10429

M3 - Article

C2 - 22580669

AN - SCOPUS:84861363111

VL - 59

SP - 1150

EP - 1154

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 116

ER -